Formosa Laboratories, Inc.

4746

TW0004746003

Pharmaceuticals

End-of-day quote Taiwan S.E. Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
95.4 ^TWD	+3.36%		+1.49%	-6.47%

03-12	Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-12	Formosa Laboratories, Inc. Approves Dividend Distribution for Full Year Ended December 31, 2023	CI

Formosa Laboratories, Inc. Announces Appointment of New Members of Audit Committee

June 27, 2023 at 03:57 am

Formosa Laboratories, Inc. announced appointment of new member of the Audit Committee of the Company. Date of occurrence of the change: June 27, 2023. Name of the new position holder: Chaung,Tza-Zen and Chang,Ting-Jun.

Resume of the new position holder: Chaung,Tza-Zen /Technical Director, SCH Life Sciences Co. Ltd. and Chang,Ting-Jung /President, Ensure & Co., CPAs. Reason for the change: To elect additional Independent Director.

Original term: June 23, 2022~June 22, 2025. Effective date of the new member: June 27, 2023.

Latest news about Formosa Laboratories, Inc.

Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Formosa Laboratories, Inc. Approves Dividend Distribution for Full Year Ended December 31, 2023	03-12	CI
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance	03-07	MT
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals	03-07	MT
Formosa Laboratories, Inc. Announces Change of Members of the Sustainable Development Committee	11-10	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Formosa Laboratories, Inc. Appoints Lin Chien-Fei as Chief Information Security Officer	23-08-10	CI
Formosa Laboratories, Inc. Announces Cash Dividend, Payable on September 22, 2023	23-08-04	CI
Formosa Laboratories, Inc. Announces Appointment of New Members of Audit Committee	23-06-27	CI
Formosa Laboratories, Inc. Approves Independent Directors Elections	23-06-27	CI
Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
HCmed Innovations, Formosa Laboratories, and Formosa Pharmaceuticals Signs MoU to Form A Global CDMO for Inhalation Treatment Drugs	22-03-06	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-04	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-11	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI
Formosa Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-13	CI
Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-29	CI

Chart Formosa Laboratories, Inc.

Duration

Period

More charts

Company Profile

Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.

Sector

Pharmaceuticals

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Formosa Laboratories, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

95.4 TWD

Average target price

135 TWD

Spread / Average Target

+41.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FORMOSA LABORATORIES, INC.	-6.47%	356M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.51%	238B
NOVARTIS AG	+7.13%	204B
ROCHE HOLDING AG	-6.34%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals